Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Tesla’s Results to Be Pivotal for TSLA Stock

By Chris Lau, InvestorPlace Contributor

Markets have high expectations for TSLA. It might exceed them in the quarter, boosting Tesla stock towards analysts' average price target..

Why Advanced Micro Devices Stock Pulled Back From $34 In The Past Week

By Chris Lau, InvestorPlace Contributor

Though Advanced Micro Devices stock fell from 52-week highs, AMD stock is still in an uptrend. What will keep the shares moving up?

Nio Stock Increasingly Looks Like It’s Worth Revisiting

By Chris Lau, InvestorPlace Contributor

Nio reported unit sales of ES8 exceeding its own estimates. This may be the beginning of Nio stock resurgence.

The Short-Term Earnings Numbers for CGC Stock Aren’t Most Important

By Chris Lau, InvestorPlace Contributor

Shares of CGC stock will move after its earnings report, but what really matters is the long-term growth narrative for Canopy.

CVS Stock Has More Going for It Than Just a 3.69% Dividend Yield

By Chris Lau, InvestorPlace Contributor

A judge is challenging the CVS Health-Aetna deal and the drug store sector is out of favor. So when will the discount on CVS stock end?

Load More